Premium
Nandrolone slows hindlimb bone loss in a rat model of bone loss due to denervation
Author(s) -
Cardozo Christopher P.,
Qin Weiping,
Peng Yuanzhen,
Liu Xuan,
Wu Yong,
Pan Jiangping,
Bauman William A.,
Zaidi Mone,
Sun Li
Publication year - 2010
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/j.1749-6632.2009.05313.x
Subject(s) - nandrolone , denervation , hindlimb , medicine , femur , sciatic nerve , endocrinology , muscle atrophy , tibia , bone mineral , anabolism , atrophy , osteoporosis , anatomy , surgery
Nandrolone is an anabolic steroid that has been demonstrated to reduce the loss of bone and muscle from hindlimb unweighting and to slow muscle atrophy after nerve transection. To determine whether nandrolone has the ability to protect bone against loss due to disuse after denervation, male rats underwent sciatic nerve transaction, followed 28 days later by treatment with nandrolone or vehicle for 28 days. Bone mineral density (BMD) was determined 28 days later or 56 days after nerve transection. Denervation led to reductions in BMD of 7% and 12% for femur and tibia, respectively. Nandrolone preserved 80% and 60% of BMD in femur and tibia, respectively, demonstrating that nandrolone administration significantly reduced loss of BMD from denervation. This study offers a potential novel pharmacological strategy for use of nandrolone to reduce bone loss in severe disuse‐ and denervation‐related bone loss, such as that which occurs after spinal cord injury.